# US 2013/0252954 A2 · Crystal of amide compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252954 A2
- Document ID: US20130252954A2
- Status: Published application
- Kind: A2
- Application number: 13/704,039
- Filed: 2011-06-15
- Published: 2013-09-26
- Earliest claimed: 2011-06-15
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Masato KITAYAMA
- Web page: https://patentgrep.com/patent/US20130252954A2

## CPC

- C07D 413/14: containing three or more hetero rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provision of crystal of 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride which has a superior rennin inhibitory activity and is useful as a prophylactic or therapeutic agent for hypertension and various organ disorders caused by hypertension, and the like. Crystal of 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride having an X-ray powder diffraction pattern showing characteristic peaks at interplanar spacings (d) of around 26.43±0.2, 7.62±0.2 and 4.32±0.2 angstroms.

## Claims

### Claim 1

A crystal of 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride having an powder X-ray diffraction pattern showing characteristic peaks at interplanar spacings (d) around 26.43±0.2, 7.62±0.2 and 4.32±0.2 angstroms.

### Claim 2

A crystal of 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride having an powder X-ray diffraction pattern showing characteristic peaks at interplanar spacings (d) of around 26.43±0.2, 7.62±0.2, 4.32±0.2, 3.08±0.2, 2.59±0.2 and 2.33±0.2 angstroms.

### Claim 3 (depends on 1, 2)

A medicament comprising the crystal of claim 1 or 2.

### Claim 4 (depends on 3)

The medicament of claim 3, which is a rennin inhibitor.

### Claim 5 (depends on 3)

The medicament of claim 3, which is a prophylactic or therapeutic agent for a circulatory disease.

### Claim 6 (depends on 3)

The medicament of claim 3, which is a prophylactic or therapeutic agent for hypertension and/or various organ disorders caused by hypertension.

### Claim 7 (depends on 3)

The medicament of claim 3, which is a prophylactic or therapeutic agent for a renal disease.

### Claim 8 (depends on 1, 2)

A method for the prophylaxis or treatment of a circulatory disease in a mammal, comprising administering an effective amount of the crystal of claim 1 or 2 to said mammal.

### Claim 9 (depends on 1, 2)

A method for the prophylaxis or treatment of hypertension and/or various organ disorders caused by hypertension in a mammal, comprising administering an effective amount of the crystal of claim 1 or 2 to said mammal.

### Claim 10 (depends on 1, 2)

A method for the prophylaxis or treatment of a renal disease in a mammal, comprising administering an effective amount of the crystal of claim 1 or 2 to said mammal.

### Claim 11 (depends on 1, 2)

Use of the crystal of claim 1 or 2 for the production of a prophylactic or therapeutic agent for a circulatory disease.

### Claim 12 (depends on 1, 2)

Use of the crystal of claim 1 or 2 for the production of a prophylactic or therapeutic agent for hypertension and/or various organ disorders caused by hypertension.

### Claim 13 (depends on 1, 2)

Use of the crystal of claim 1 or 2 for the production of a prophylactic or therapeutic agent for a renal disease.

### Claim 14 (depends on 1, 2)

The crystal of claim 1 or 2 for use in the prophylaxis or treatment of a circulatory disease.

### Claim 15 (depends on 1, 2)

The crystal of claim 1 or 2 for use in the prophylaxis or treatment of hypertension and/or various organ disorders caused by hypertension.

### Claim 16 (depends on 1, 2)

The crystal of claim 1 or 2 for use in the prophylaxis or treatment of a renal disease.
